Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.
about
Acute kidney injury: preclinical innovations, challenges, and opportunities for translationPretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss.Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cellsPolyreactive antibodies developing amidst humoral rejection of human kidney grafts bind apoptotic cells and activate complement.Endothelial Cells in Antibody-Mediated Rejection of Kidney Transplantation: Pathogenesis Mechanisms and Therapeutic Implications.Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy.Antibodies against Apoptotic Cells Present in End-stage Lung Disease Patients Do Not Correlate with Clinical Outcome after Lung Transplantation.The importance of non-HLA antibodies in transplantation.The Emerging Importance of Non-HLA Autoantibodies in Kidney Transplant Complications.Clinical and immunological relevance of antibodies in solid organ transplantation.Polyomavirus Reactivation and Immune Responses to Kidney-Specific Self-Antigens in Transplantation.Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection.Impact of Non-Human Leukocyte Antigen-Specific Antibodies in Kidney and Heart Transplantation.Role of alloimmunity and autoimmunity in allograft rejection.Acute Rejection Phenotypes in the Current Era of Immunosuppression: A Single-Center Analysis.Antibodies beyond HLA.Protein biomarkers in renal transplantation.Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation.Anti-LG3 Antibodies Aggravate Renal Ischemia-Reperfusion Injury and Long-Term Renal Allograft Dysfunction.The Role of the Endothelium during Antibody-Mediated Rejection: From Victim to Accomplice.Prevalence of polyreactive innate clones among graft--infiltrating B cells in human cardiac allograft vasculopathy.The perlecan fragment LG3 regulates homing of mesenchymal stem cells and neointima formation during vascular rejection.Post-Transplant Natural Antibodies Associate with Kidney Allograft Injury and Reduced Long-Term Survival.The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection.Endothelial Dysfunction in Kidney Transplantation.Graft versus Host Disease: From Basic Pathogenic Principles to DNA Damage Response and Cellular Senescence.Do natural antibodies have a detrimental effect after kidney transplantation?
P2860
Q26786667-DD239D04-3EC1-4A6C-AB8B-CF7CCDBCDB4BQ33998148-F038FBB5-9BF8-4522-AAFA-7BE5EB7B6936Q37015691-7CDFCE30-5079-4D56-AAF9-DFE64CAD40F0Q37394636-55559687-DB48-41EE-B3CC-7B6509241FADQ37642331-67B1FCB6-2F90-4645-9B68-BAEF7059B784Q37660263-FF26AB42-1129-4D27-A4A6-42D61217F540Q37712485-C432BDAF-7057-460D-94FE-FA8D73172EFDQ38877375-0B80F002-8C09-40D9-9647-8C5502BD3D30Q38995184-4DCC9425-673C-48F6-AC8D-D944C3A977DFQ39015291-238820AA-CEB3-455B-8EC5-B74FE5C91223Q39207543-C8FBC651-46C9-4E9D-8C79-87266F883846Q39217968-42984E96-549B-40F5-B3BF-167ED8AE0D83Q39268286-8377E2A9-FE66-4256-A450-9CBDB1CD0352Q41226453-88100218-2023-4C32-BE97-CE8BA7FEB6BAQ41946081-11934190-6786-4ECE-99E0-F0C3B00DC3AAQ43865301-C3385BB1-2C84-4DC5-8639-D9EF8DBF2FEEQ46023013-C26079ED-F430-4434-9D45-D1EAFD1C981FQ46409439-05885D10-70C0-4B47-AD3B-4FB82B31690BQ48055653-15C30CFB-545E-44DC-B42C-759DD43A63A5Q49521510-469CC29B-D30C-4DBD-8B37-86F879B5898AQ50063911-63132F17-FD2D-4614-A973-BA04338AA247Q50437673-D26B4376-1B69-49F5-8DEB-62B4A033AB09Q52618068-C6DB1247-4065-4409-83CE-FA57846F7E8AQ53241382-41FC22B3-65FF-49B4-8A71-00F923762966Q54983740-4DEABE62-EDE8-40EA-A288-2B45CD7F2CC4Q55045366-59993900-3384-408D-BA0F-2749D2C318A3Q58566650-91775276-277E-4B71-8464-2BC4B03B2196
P2860
Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.
@ast
Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.
@en
Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.
@nl
type
label
Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.
@ast
Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.
@en
Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.
@nl
prefLabel
Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.
@ast
Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.
@en
Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.
@nl
P2093
P2860
P356
P1476
Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.
@en
P2093
D Beillevaire
F Echeverry
H Cardinal
M J Hébert
N Brassard
P2860
P304
P356
10.1111/AJT.12168
P407
P577
2013-02-22T00:00:00Z